Logo image of NPCE

NEUROPACE INC (NPCE) Stock Fundamental Analysis

USA - NASDAQ:NPCE - US6412881053 - Common Stock

10.13 USD
-0.49 (-4.61%)
Last: 10/29/2025, 6:50:29 PM
10.13 USD
0 (0%)
After Hours: 10/29/2025, 6:50:29 PM
Fundamental Rating

2

Taking everything into account, NPCE scores 2 out of 10 in our fundamental rating. NPCE was compared to 189 industry peers in the Health Care Equipment & Supplies industry. NPCE has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, NPCE is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NPCE had negative earnings in the past year.
In the past year NPCE has reported a negative cash flow from operations.
NPCE had negative earnings in each of the past 5 years.
In the past 5 years NPCE always reported negative operating cash flow.
NPCE Yearly Net Income VS EBIT VS OCF VS FCFNPCE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

NPCE's Return On Assets of -24.45% is in line compared to the rest of the industry. NPCE outperforms 46.03% of its industry peers.
NPCE's Return On Equity of -133.46% is on the low side compared to the rest of the industry. NPCE is outperformed by 66.67% of its industry peers.
Industry RankSector Rank
ROA -24.45%
ROE -133.46%
ROIC N/A
ROA(3y)-33.52%
ROA(5y)-34.1%
ROE(3y)-211.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NPCE Yearly ROA, ROE, ROICNPCE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

NPCE has a Gross Margin of 75.74%. This is amongst the best in the industry. NPCE outperforms 87.83% of its industry peers.
In the last couple of years the Gross Margin of NPCE has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for NPCE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 75.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.03%
GM growth 5Y0.65%
NPCE Yearly Profit, Operating, Gross MarginsNPCE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

3

2. Health

2.1 Basic Checks

NPCE does not have a ROIC to compare to the WACC, probably because it is not profitable.
NPCE has more shares outstanding than it did 1 year ago.
The number of shares outstanding for NPCE has been increased compared to 5 years ago.
NPCE has a worse debt/assets ratio than last year.
NPCE Yearly Shares OutstandingNPCE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
NPCE Yearly Total Debt VS Total AssetsNPCE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -3.69, we must say that NPCE is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -3.69, NPCE is not doing good in the industry: 66.14% of the companies in the same industry are doing better.
A Debt/Equity ratio of 3.02 is on the high side and indicates that NPCE has dependencies on debt financing.
NPCE has a Debt to Equity ratio of 3.02. This is amonst the worse of the industry: NPCE underperforms 85.19% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.02
Debt/FCF N/A
Altman-Z -3.69
ROIC/WACCN/A
WACC8.6%
NPCE Yearly LT Debt VS Equity VS FCFNPCE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 5.47 indicates that NPCE has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.47, NPCE belongs to the top of the industry, outperforming 80.42% of the companies in the same industry.
A Quick Ratio of 4.51 indicates that NPCE has no problem at all paying its short term obligations.
NPCE has a better Quick ratio (4.51) than 79.37% of its industry peers.
Industry RankSector Rank
Current Ratio 5.47
Quick Ratio 4.51
NPCE Yearly Current Assets VS Current LiabilitesNPCE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 22.94% over the past year.
Looking at the last year, NPCE shows a very strong growth in Revenue. The Revenue has grown by 23.32%.
Measured over the past years, NPCE shows a quite strong growth in Revenue. The Revenue has been growing by 16.67% on average per year.
EPS 1Y (TTM)22.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)23.32%
Revenue growth 3Y20.93%
Revenue growth 5Y16.67%
Sales Q2Q%22.14%

3.2 Future

Based on estimates for the next years, NPCE will show a very strong growth in Earnings Per Share. The EPS will grow by 21.17% on average per year.
The Revenue is expected to grow by 18.68% on average over the next years. This is quite good.
EPS Next Y8.47%
EPS Next 2Y11.97%
EPS Next 3Y19.33%
EPS Next 5Y21.17%
Revenue Next Year20.22%
Revenue Next 2Y12.92%
Revenue Next 3Y16.87%
Revenue Next 5Y18.68%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
NPCE Yearly Revenue VS EstimatesNPCE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M
NPCE Yearly EPS VS EstimatesNPCE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NPCE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NPCE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NPCE Price Earnings VS Forward Price EarningsNPCE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NPCE Per share dataNPCE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as NPCE's earnings are expected to grow with 19.33% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.97%
EPS Next 3Y19.33%

More info and screens

0

5. Dividend

5.1 Amount

NPCE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROPACE INC

NASDAQ:NPCE (10/29/2025, 6:50:29 PM)

After market: 10.13 0 (0%)

10.13

-0.49 (-4.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners60.77%
Inst Owner Change0.11%
Ins Owners2.49%
Ins Owner Change0.78%
Market Cap335.10M
Revenue(TTM)88.57M
Net Income(TTM)-25942000
Analysts84.29
Price Target17.19 (69.69%)
Short Float %4.31%
Short Ratio6.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.08%
Min EPS beat(2)-14.56%
Max EPS beat(2)14.72%
EPS beat(4)3
Avg EPS beat(4)12.89%
Min EPS beat(4)-14.56%
Max EPS beat(4)30.58%
EPS beat(8)7
Avg EPS beat(8)16.32%
EPS beat(12)11
Avg EPS beat(12)15.67%
EPS beat(16)11
Avg EPS beat(16)8.03%
Revenue beat(2)1
Avg Revenue beat(2)0.48%
Min Revenue beat(2)-0.11%
Max Revenue beat(2)1.08%
Revenue beat(4)2
Avg Revenue beat(4)2.14%
Min Revenue beat(4)-0.6%
Max Revenue beat(4)8.22%
Revenue beat(8)6
Avg Revenue beat(8)3.61%
Revenue beat(12)10
Avg Revenue beat(12)7.12%
Revenue beat(16)12
Avg Revenue beat(16)4.63%
PT rev (1m)0%
PT rev (3m)-2.48%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.95%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.81%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.78
P/FCF N/A
P/OCF N/A
P/B 17.24
P/tB 17.24
EV/EBITDA N/A
EPS(TTM)-0.84
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS2.68
BVpS0.59
TBVpS0.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -24.45%
ROE -133.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 75.74%
FCFM N/A
ROA(3y)-33.52%
ROA(5y)-34.1%
ROE(3y)-211.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.03%
GM growth 5Y0.65%
F-Score5
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity 3.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.69%
Cap/Sales 0.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.47
Quick Ratio 4.51
Altman-Z -3.69
F-Score5
WACC8.6%
ROIC/WACCN/A
Cap/Depr(3y)83.43%
Cap/Depr(5y)79.26%
Cap/Sales(3y)0.66%
Cap/Sales(5y)0.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y8.47%
EPS Next 2Y11.97%
EPS Next 3Y19.33%
EPS Next 5Y21.17%
Revenue 1Y (TTM)23.32%
Revenue growth 3Y20.93%
Revenue growth 5Y16.67%
Sales Q2Q%22.14%
Revenue Next Year20.22%
Revenue Next 2Y12.92%
Revenue Next 3Y16.87%
Revenue Next 5Y18.68%
EBIT growth 1Y19.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.5%
EBIT Next 3Y26.38%
EBIT Next 5YN/A
FCF growth 1Y43.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.29%
OCF growth 3YN/A
OCF growth 5YN/A

NEUROPACE INC / NPCE FAQ

Can you provide the ChartMill fundamental rating for NEUROPACE INC?

ChartMill assigns a fundamental rating of 2 / 10 to NPCE.


Can you provide the valuation status for NEUROPACE INC?

ChartMill assigns a valuation rating of 0 / 10 to NEUROPACE INC (NPCE). This can be considered as Overvalued.


Can you provide the profitability details for NEUROPACE INC?

NEUROPACE INC (NPCE) has a profitability rating of 1 / 10.


What is the earnings growth outlook for NEUROPACE INC?

The Earnings per Share (EPS) of NEUROPACE INC (NPCE) is expected to grow by 8.47% in the next year.